drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Recombinant anti-EpCAM×CD3 T-cell–redirecting bispecific antibody administered by IV infusion; binds EpCAM on tumor cells and CD3 on T cells to form an immune synapse, activate CD3/TCR signaling, and induce T-cell–mediated cytotoxicity and cytokine release against EpCAM-positive epithelial cancers. Also referred to as 'Recombinant Anti-EpCAM-CD3 Antibody Injection.'
nci_thesaurus_concept_id
C202933
nci_thesaurus_definition
A T-cell engager (TCE) and bispecific antibody composed of two fragments targeting the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and one targeting the T-cell surface glycoprotein CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody A-337 targets and binds to EpCAM on EpCAM-expressing tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Recombinant bispecific antibody that simultaneously binds EpCAM (CD326) on epithelial tumor cells and CD3 on T cells, forming an immune synapse that activates CD3/TCR signaling and redirects cytotoxic T-cell activity to lyse EpCAM-positive tumor cells with associated cytokine release.
drug_name
A-337
nct_id_drug_ref
NCT06093698